{"id":"placebo-part-ii","safety":{"commonSideEffects":[]},"_chembl":null,"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Placebo Part II","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T02:35:55.208099+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T02:36:01.650544+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Placebo Part II","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T02:36:02.422139+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL20226/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T02:36:03.396124+00:00"}},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a placebo, this product contains no active pharmaceutical ingredient and produces therapeutic effects primarily through psychobiological mechanisms such as expectation and conditioning. It is used as a control or comparator in clinical trials and may be marketed for specific indications where placebo response is clinically relevant.","oneSentence":"Placebo Part II is an inert substance with no active pharmacological mechanism.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:01:17.259Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T02:36:05.325211+00:00","fieldsConflicting":0,"overallConfidence":0.95},"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT04534556","phase":"NA","title":"Wireless Nerve Stimulation Device To Enhance Recovery After Stroke","status":"RECRUITING","sponsor":"Baylor Research Institute","startDate":"2021-09-01","conditions":"Stroke, Chronic Stroke, Upper Extremity Paresis","enrollment":42},{"nctId":"NCT03850964","phase":"PHASE2, PHASE3","title":"Effects of Pazopanib on Hereditary Hemorrhagic Telangiectasia Related Epistaxis and Anemia (Paz)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cure HHT","startDate":"2023-05-08","conditions":"Hereditary Hemorrhagic Telangiectasia, Epistaxis, Anemia","enrollment":70},{"nctId":"NCT05440643","phase":"PHASE1, PHASE2","title":"Peanut Sublingual Immunotherapy (SLIT)-Tablet for Treatment of Peanut Allergy","status":"ACTIVE_NOT_RECRUITING","sponsor":"ALK-Abelló A/S","startDate":"2022-09-07","conditions":"Peanut Allergy","enrollment":192},{"nctId":"NCT03100149","phase":"PHASE2","title":"A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2017-06-27","conditions":"Parkinson's Disease","enrollment":316},{"nctId":"NCT05406362","phase":"PHASE1, PHASE2","title":"Assess Safety and Efficacy of VAD044 in HHT Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vaderis Therapeutics AG","startDate":"2022-07-18","conditions":"Hereditary Hemorrhagic Telangiectasia (HHT)","enrollment":75},{"nctId":"NCT05396105","phase":"PHASE2, PHASE3","title":"Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema","status":"ENROLLING_BY_INVITATION","sponsor":"Pharvaris Netherlands B.V.","startDate":"2022-12-28","conditions":"Hereditary Angioedema, Hereditary Angioedema Type I, Hereditary Angioedema Type II","enrollment":150},{"nctId":"NCT06602453","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of GDC-8264 in Preventing Cardiac Surgery-Associated Acute Kidney Injury (AKI) and Major Adverse Kidney Events (MAKE)","status":"TERMINATED","sponsor":"Genentech, Inc.","startDate":"2025-01-17","conditions":"Acute Kidney Injury","enrollment":67},{"nctId":"NCT06834932","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of AZD0780 in Participants With Dyslipidaemia","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-12-06","conditions":"Dyslipidaemia","enrollment":360},{"nctId":"NCT06166056","phase":"PHASE1, PHASE2","title":"A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Inhaled CHF6333 After Single Doses in Healthy Volunteers and After Single and Repeated Doses in Subjects With Bronchiectasis","status":"RECRUITING","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2023-11-29","conditions":"Bronchiectasis","enrollment":45},{"nctId":"NCT04288245","phase":"NA","title":"Targeted Plasticity Therapy for Upper Limb Rehabilitation in Spinal Cord Injuries","status":"ACTIVE_NOT_RECRUITING","sponsor":"Baylor Research Institute","startDate":"2021-02-15","conditions":"Spinal Cord Injuries, Upper Extremity Paresis","enrollment":20},{"nctId":"NCT05726292","phase":"PHASE2","title":"A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2025-01-06","conditions":"Prostate Cancer, Prostate Adenocarcinoma","enrollment":90},{"nctId":"NCT06306014","phase":"PHASE1, PHASE2","title":"Evaluation of EXL01, a New Live Biotherapeutic Product to Prevent Recurrence of Clostridioides Difficile Infection in High-risk Patients","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2024-05-07","conditions":"Clostridioides Difficile Infection, Recurrent Infection","enrollment":56},{"nctId":"NCT07047703","phase":"PHASE1, PHASE2","title":"EAST-1 (ERAP-inhibition in Axial Spondyloarthritis Trial - 1)","status":"RECRUITING","sponsor":"Grey Wolf Therapeutics","startDate":"2025-07-28","conditions":"Axial Spondyloarthritis (AxSpA)","enrollment":141},{"nctId":"NCT05469737","phase":"PHASE2, PHASE3","title":"A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With International Prognostic Scoring System Revised (IPSS-R) Low- or Intermediate-risk Myelodysplastic Syndrome (MDS)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2022-12-14","conditions":"Myelodysplastic Syndromes","enrollment":230},{"nctId":"NCT06515002","phase":"PHASE1, PHASE2","title":"A Study to Test How Well BI 3720931 is Tolerated and Whether it Improves Lung Function in People With Cystic Fibrosis (Lenticlair™ 1)","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2024-11-04","conditions":"Cystic Fibrosis","enrollment":5},{"nctId":"NCT03157635","phase":"PHASE1, PHASE2","title":"Study to Assess Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Healthy Volunteers and Participants With Paroxysmal Nocturnal Hemoglobinuria","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2016-11-14","conditions":"Paroxysmal Hemoglobinuria, Nocturnal","enrollment":59},{"nctId":"NCT07356271","phase":"EARLY_PHASE1","title":"Effects of Mouthwashes on the Oral Microbiome and Systemic Health","status":"NOT_YET_RECRUITING","sponsor":"University of Plymouth","startDate":"2026-02-01","conditions":"Hypertension","enrollment":200},{"nctId":"NCT06106828","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-11-15","conditions":"Thyroid Eye Disease","enrollment":127},{"nctId":"NCT07403487","phase":"PHASE2","title":"Phase II Trial of RC1416 Injection in Asthma","status":"NOT_YET_RECRUITING","sponsor":"Nanjing RegeneCore Biotech Co., Ltd.","startDate":"2026-03-10","conditions":"Moderate to Severe Asthma","enrollment":195},{"nctId":"NCT07402551","phase":"PHASE2","title":"Phase II Study of RC1416 Injection in COPD","status":"NOT_YET_RECRUITING","sponsor":"Nanjing RegeneCore Biotech Co., Ltd.","startDate":"2026-03-07","conditions":"Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)","enrollment":180},{"nctId":"NCT05987423","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-10-26","conditions":"Thyroid Eye Disease, TED","enrollment":131},{"nctId":"NCT06546670","phase":"PHASE1, PHASE2","title":"A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-08-15","conditions":"Sickle Cell Disease","enrollment":161},{"nctId":"NCT05721573","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis","status":"COMPLETED","sponsor":"Abcuro, Inc.","startDate":"2023-02-28","conditions":"Inclusion Body Myositis","enrollment":272},{"nctId":"NCT06790095","phase":"PHASE2","title":"TRACK-TBI Precision Medicine Part 3 - Option II","status":"ENROLLING_BY_INVITATION","sponsor":"University of California, San Francisco","startDate":"2026-02","conditions":"Traumatic Brain Injury","enrollment":26},{"nctId":"NCT06194656","phase":"PHASE2","title":"Clinical Trial of SIBP-03 in Patients With Head and Neck Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Shanghai Institute Of Biological Products","startDate":"2024-09-27","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":81},{"nctId":"NCT06151964","phase":"PHASE1, PHASE2","title":"A Trial to Learn How Safe AZD9550 Monotherapy and Combined With AZD6234 is in People With or Without Type 2 Diabetes Who Are Living With Obesity and Overweight","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2023-09-29","conditions":"Overweight and Obesity","enrollment":118},{"nctId":"NCT07318883","phase":"PHASE2, PHASE3","title":"A Phase II/III Clinical Study to Evaluate HLX07 in Combination With Serplulimab and Chemotherapy Versus Placebo in Combination With Serplulimab or Pembrolizumab and Chemotherapy as First-Line Treatment in Advanced Squamous Non-Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2026-03","conditions":"Squamous NSCLC","enrollment":720},{"nctId":"NCT07172646","phase":"PHASE1, PHASE2","title":"A Study of SRSD216 in Patients With Elevated Lipoprotein (a)","status":"RECRUITING","sponsor":"Sirius Therapeutics Co., Ltd.","startDate":"2025-04-07","conditions":"Hyperlipoproteinemia (a)","enrollment":84},{"nctId":"NCT07203755","phase":"PHASE1","title":"Clinical Trial of the Adsorbed Acellular Pertussis (Tricomponent) DTaP-Haemophilus Influenzae Type b (Conjugate)-ACYW135 Group Meningococcal (Conjugate) Combined Vaccine","status":"RECRUITING","sponsor":"CanSino Biologics Inc.","startDate":"2025-12-19","conditions":"Diphtheria, Tetanus and Acellular Pertussis, Epidemic Meningitis, Haemophilus Influenzae Type B Infection","enrollment":260},{"nctId":"NCT04090957","phase":"PHASE3","title":"Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women (E4Comfort II)","status":"COMPLETED","sponsor":"Estetra","startDate":"2019-09-27","conditions":"Vasomotor Symptoms, Menopausal Symptoms","enrollment":1015},{"nctId":"NCT04939597","phase":"PHASE3","title":"A Study to See if Memantine Protects the Brain During Radiation Therapy Treatment for a Brain Tumor","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2022-05-10","conditions":"Central Nervous System Carcinoma","enrollment":192},{"nctId":"NCT06877364","phase":"PHASE1, PHASE2","title":"Safety, Tolerability and Efficacy of GcMAF in Patients With Chronic Inflammatory Diseases","status":"COMPLETED","sponsor":"S.LAB (SOLOWAYS)","startDate":"2025-09-01","conditions":"Inflammation","enrollment":120},{"nctId":"NCT05307679","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of Basmisanil Treatment in Children Aged 2-14 Years With Dup15q Syndrome","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2022-12-16","conditions":"Dup15q Syndrome","enrollment":7},{"nctId":"NCT05073003","phase":"PHASE1","title":"A Study on the Safety and Immune Responses to the GVGH altSonflex1-2-3 Vaccine Against Shigellosis in Adults, Children, and Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-10-06","conditions":"Diarrhoea","enrollment":551},{"nctId":"NCT07264595","phase":"PHASE1, PHASE2","title":"A Study (Phase 1b/2) of GS3-007a Oral Treatment in Children With Growth Hormone Deficiency (PGHD)","status":"NOT_YET_RECRUITING","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","startDate":"2025-12","conditions":"Pediatric Growth Hormone Deficiency","enrollment":88},{"nctId":"NCT07237425","phase":"PHASE1","title":"Intralesional Ronkyla Plus Injection for the Treatment of Superficial Lipoma","status":"RECRUITING","sponsor":"Glonova Pharma Co., Ltd","startDate":"2025-11-14","conditions":"Lipoma, Submental Fullness","enrollment":56},{"nctId":"NCT03039673","phase":"PHASE2","title":"MIROCALS: Modifying Immune Response and OutComes in ALS","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2017-06-19","conditions":"Amyotrophic Lateral Sclerosis","enrollment":304},{"nctId":"NCT05162586","phase":"PHASE2","title":"The WILLOW Study With M5049 in SLE and CLE (SCLE and/or DLE) (WILLOW)","status":"COMPLETED","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2022-03-31","conditions":"Systemic Lupus Erythematosus","enrollment":456},{"nctId":"NCT03687957","phase":"PHASE1, PHASE2","title":"rhIL-7-hyFc on Increasing Lymphocyte Counts in Patients With Newly Diagnosed Non-severe Lymphopenic Gliomas Following Radiation and Temozolomide","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2019-01-04","conditions":"Glioma","enrollment":42},{"nctId":"NCT07043452","phase":"EARLY_PHASE1","title":"Measuring Acute Drug Demand in Humans II","status":"WITHDRAWN","sponsor":"Johns Hopkins University","startDate":"2025-11-15","conditions":"Healthy Volunteers","enrollment":""},{"nctId":"NCT06776432","phase":"PHASE2","title":"Safety and Efficacy Study of Sivopixant, Acetazolamide and SASS-001 in Sleep Apnea","status":"RECRUITING","sponsor":"Shionogi Apnimed Sleep Science","startDate":"2025-04-02","conditions":"Sleep Apnea","enrollment":60},{"nctId":"NCT07199946","phase":"PHASE1, PHASE2","title":"A Phase I/II Trial to Preserve Residual Insulin Secretion in Children With Recent Onset Type 1 Diabetes by Giving Verapamil","status":"RECRUITING","sponsor":"Johnny Ludvigsson","startDate":"2025-08-06","conditions":"Type 1 Diabetes","enrollment":36},{"nctId":"NCT05769582","phase":"PHASE2, PHASE3","title":"Safety, Tolerability and Efficacy of AntiBKV as Treatment of BKV Infection in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Memo Therapeutics AG","startDate":"2023-04-10","conditions":"BK Viremia; BKV DNAemia","enrollment":95},{"nctId":"NCT06830395","phase":"PHASE2","title":"Study of CM313 in Subject With IgA Nephropathy","status":"NOT_YET_RECRUITING","sponsor":"Keymed Biosciences Co.Ltd","startDate":"2025-09","conditions":"IgA Nephropathy","enrollment":106},{"nctId":"NCT03971695","phase":"PHASE1","title":"A Study to Test How Well Healthy Men Tolerate Different Doses of BI 706321","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2019-06-18","conditions":"Healthy","enrollment":73},{"nctId":"NCT05844735","phase":"PHASE1","title":"A Randomized Placebo- and Active Comparator-controlled Study to Evaluate the Photosafety of SAR441566","status":"COMPLETED","sponsor":"Sanofi","startDate":"2023-05-22","conditions":"Rheumatoid Arthritis","enrollment":60},{"nctId":"NCT07027345","phase":"PHASE2","title":"A Phase II, Placebo Controlled, Clinical Trial of Topical TolaSure Targeting Aggregated Mutant Keratin in Epidermolysis Bullosa Simplex","status":"RECRUITING","sponsor":"BioMendics, LLC","startDate":"2025-09","conditions":"Epidermolysis Bullosa Simplex","enrollment":40},{"nctId":"NCT07129382","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Efficacy and Safety of CS32582 in Participants With Moderate to Severe Plaque Psoriasis","status":"RECRUITING","sponsor":"Chipscreen Biosciences, Ltd.","startDate":"2025-09-08","conditions":"Plaque Psoriasis","enrollment":220},{"nctId":"NCT05298254","phase":"PHASE1, PHASE2","title":"A Study on the Reactogenicity, Safety, Immune Response, and Efficacy of a Targeted Immunotherapy Against HSV in Healthy Participants Aged 18-40 Years or in Participants Aged 18-60 Years With Recurrent Genital Herpes","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-03-07","conditions":"Herpes Simplex","enrollment":505},{"nctId":"NCT05695261","phase":"PHASE2","title":"Evaluating the Safety and Efficacy of Oral Encapsulated Microbiota Transplantation Therapy in Peanut Allergic Patients","status":"RECRUITING","sponsor":"Rima Rachid","startDate":"2023-06-08","conditions":"Allergy, Peanut, Peanut Allergy, Peanut Hypersensitivity","enrollment":37},{"nctId":"NCT06990776","phase":"PHASE2","title":"A Clinical Trial to Evaluate the Efficacy and Safety of TQA3605 Tablets in Treatment-naive Chronic HBV-infected Subjects","status":"WITHDRAWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2025-07-09","conditions":"Chronic Hepatitis B","enrollment":""},{"nctId":"NCT07098117","phase":"PHASE1","title":"A Randomized, Double-blind, Placebo-controlled Phase I Clinical Trial to Evaluate the Safety and Pharmacokinetic Profile of Single and Multiple Dose Escalation Topical Dermal Administration of SHR0302 Alkali Gel in Healthy Subjects","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2024-06-19","conditions":"Preoperative Sedation of Adults","enrollment":32},{"nctId":"NCT05047185","phase":"PHASE2","title":"Dose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Type I or Type II","status":"COMPLETED","sponsor":"Pharvaris Netherlands B.V.","startDate":"2022-04-19","conditions":"Hereditary Angioedema, Hereditary Angioedema Type I, Hereditary Angioedema Type II","enrollment":34},{"nctId":"NCT06891625","phase":"NA","title":"Movement Performance in Persons With Chronic Back Pain","status":"RECRUITING","sponsor":"Karolinska Institutet","startDate":"2025-09-01","conditions":"Chronic Low-back Pain, Back Disorder","enrollment":40},{"nctId":"NCT07044960","phase":"PHASE1","title":"A Phase 1 Study of KHN702 Tablets in Healthy Subjects","status":"NOT_YET_RECRUITING","sponsor":"Chengdu Kanghong Pharmaceutical Group Co., Ltd.","startDate":"2025-06-21","conditions":"Healthy","enrollment":84},{"nctId":"NCT07028424","phase":"PHASE2","title":"PANORAMIX : Optimizing 1st-line NALIRIFOX and Exploring Microbiota's Role in 2nd Line Pancreatic Cancer Treatment","status":"NOT_YET_RECRUITING","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2025-07","conditions":"PDAC - Pancreatic Ductal Adenocarcinoma","enrollment":206},{"nctId":"NCT07040280","phase":"PHASE2","title":"Testing the Effect of Sulforaphane, a Compound Naturally Found in Cruciferous Vegetables, on Preventing Melanoma in Patients With a Prior History of Melanoma","status":"NOT_YET_RECRUITING","sponsor":"Eastern Cooperative Oncology Group","startDate":"2025-10-31","conditions":"Melanoma","enrollment":120},{"nctId":"NCT07041801","phase":"PHASE1, PHASE2","title":"Treatment of Systemic Lupus Erythematosus With Human Umbilical Cord Mesenchymal Stem Cells","status":"RECRUITING","sponsor":"Shenzhen Beike Bio-Technology Co., Ltd.","startDate":"2025-06-28","conditions":"Systemic Lupus Erythematosus (SLE)","enrollment":58},{"nctId":"NCT05198323","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of LT3001 Drug Product in Subjects AIS Undergoing EVT","status":"RECRUITING","sponsor":"Lumosa Therapeutics Co., Ltd.","startDate":"2022-08-11","conditions":"Acute Ischemic Stroke","enrollment":66},{"nctId":"NCT00529113","phase":"PHASE1","title":"Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer","status":"TERMINATED","sponsor":"Biogen","startDate":"2007-09-30","conditions":"Pancreatic Neoplasms, Pancreatic Cancer","enrollment":33},{"nctId":"NCT04473690","phase":"PHASE1, PHASE2","title":"KBP-201 COVID-19 Vaccine Trial in Healthy Volunteers","status":"COMPLETED","sponsor":"KBio Inc","startDate":"2020-12-30","conditions":"Covid19","enrollment":102},{"nctId":"NCT04208412","phase":"PHASE2","title":"A Phase II, Cross-over Clinical Trial Evaluating the Efficacy and Safety of KVD900 (Sebetralstat) in the On-demand Treatment of Angioedema Attacks in Adult Subjects With Hereditary Angioedema Type I or II","status":"COMPLETED","sponsor":"KalVista Pharmaceuticals, Ltd.","startDate":"2019-07-02","conditions":"Hereditary Angioedema","enrollment":84},{"nctId":"NCT04313400","phase":"PHASE1, PHASE2","title":"Topically Applied AMTX-100 CF for Adult Patients With Mild to Moderate Atopic Dermatitis","status":"COMPLETED","sponsor":"Amytrx Therapeutics, Inc.","startDate":"2020-03-10","conditions":"Atopic Dermatitis","enrollment":91},{"nctId":"NCT06048588","phase":"PHASE1, PHASE2","title":"YN001 in Healthy Subjects and Patients With Coronary Atherosclerosis","status":"COMPLETED","sponsor":"Beijing Inno Medicine Co., Ltd.","startDate":"2023-10-08","conditions":"Atherosclerotic Cardiovascular Disease","enrollment":144},{"nctId":"NCT04163562","phase":"PHASE1, PHASE2","title":"Oral Immunotherapy for Peanut Allergic Patients","status":"RECRUITING","sponsor":"InnoUp Farma S.L.","startDate":"2020-03-11","conditions":"Peanut Allergy","enrollment":50},{"nctId":"NCT02877134","phase":"PHASE2","title":"Safety and Efficacy Study of JNJ-64304500 in Participants With Moderately to Severely Active Crohn's Disease","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2016-08-25","conditions":"Crohn Disease","enrollment":388},{"nctId":"NCT06946017","phase":"NA","title":"Effect of a Fermented Dairy Protein With Prebiotic Fiber on GI Complaints","status":"RECRUITING","sponsor":"Arizona State University","startDate":"2025-03-31","conditions":"Digestive Health, Quality of Life","enrollment":114},{"nctId":"NCT00957047","phase":"PHASE3","title":"Efficacy and Safety Study of BIA 2-093 in Combination With Other Anti-Epileptic Drugs to Treat Partial Epilepsy","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2004-07","conditions":"Partial Epilepsy","enrollment":395},{"nctId":"NCT06892951","phase":"PHASE1, PHASE2","title":"CaspoNEB: Efficacy and Safety of Caspofungin Aerosols for the Curative Treatment of Pneumocystis Pneumonia","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Tours","startDate":"2025-06","conditions":"Pneumocystis Pneumonia, Pneumocystis Jirovecii Infection, Pneumocystis Infections","enrollment":100},{"nctId":"NCT00957684","phase":"PHASE3","title":"Efficacy and Safety of Eslicarbazepine Acetate as Adjunctive Therapy for Refractory Partial Seizures","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2004-07","conditions":"Refractory Partial Epilepsy","enrollment":402},{"nctId":"NCT05310253","phase":"NA","title":"Stress & Social Cognition in BPD (part 2)","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2022-02-01","conditions":"Borderline Personality Disorder","enrollment":240},{"nctId":"NCT00979576","phase":"PHASE1","title":"BIBF 1120 in Combination With Pemetrexed in Advanced Non Small Cell Lung Cancer (NSCLC)","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2009-10-16","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":19},{"nctId":"NCT06486662","phase":"PHASE1","title":"A Clinical Study Investigating OM-85-IN Safety and Tolerability in Healthy Volunteers and Mild Allergic Asthma Patients","status":"COMPLETED","sponsor":"OM Pharma SA","startDate":"2024-06-14","conditions":"Allergic Asthma","enrollment":41},{"nctId":"NCT05913752","phase":"PHASE1, PHASE2","title":"A First in Human Study of CMND-100 in Healthy and Alcohol Use Disorder (AUD) Subjects","status":"NOT_YET_RECRUITING","sponsor":"Clearmind Medicine Inc.","startDate":"2025-03-31","conditions":"Alcohol Use Disorder","enrollment":84},{"nctId":"NCT02662712","phase":"PHASE1","title":"A Study of Orally Administered JNJ-56136379 to Evaluate Safety, Tolerability and Pharmacokinetics After Single Ascending Doses and One Multiple Dose Regimen in Healthy Participants (Part I), and After Multiple Dose Regimens in Participants With Chronic Hepatitis B (Part II)","status":"COMPLETED","sponsor":"Janssen Sciences Ireland UC","startDate":"2015-12-17","conditions":"Healthy, Hepatitis, Chronic","enrollment":87},{"nctId":"NCT05427253","phase":"PHASE1","title":"First-in-human Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of C106 in Healthy Subjects","status":"COMPLETED","sponsor":"Vicore Pharma AB","startDate":"2022-06-08","conditions":"Safety Issues, Tolerance, Idiopathic Pulmonary Fibrosis","enrollment":80},{"nctId":"NCT06535308","phase":"PHASE1","title":"BnH-015B Clinical Trial in Moderate Alzheimer's Disease","status":"RECRUITING","sponsor":"BnH Research","startDate":"2024-10-22","conditions":"Alzheimer Disease","enrollment":92},{"nctId":"NCT06736912","phase":"PHASE1","title":"This Study Aims to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties and Food Effect of IN-114199 in Healthy Participants","status":"NOT_YET_RECRUITING","sponsor":"HK inno.N Corporation","startDate":"2024-12-16","conditions":"Chronic Idiopathic Constipation","enrollment":80},{"nctId":"NCT03553836","phase":"PHASE3","title":"Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-09-12","conditions":"Melanoma","enrollment":976},{"nctId":"NCT02809105","phase":"PHASE3","title":"A Study of Oral Dosing of ASP0456 in Patients With Chronic Constipation","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2016-06-24","conditions":"Chronic Constipation","enrollment":186},{"nctId":"NCT06619210","phase":"PHASE2","title":"A Trial to Evaluate the Safety and Efficacy of HL231 Solution for Inhalation in Patients with COPD","status":"COMPLETED","sponsor":"Haisco Pharmaceutical Group Co., Ltd.","startDate":"2022-01-12","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":102},{"nctId":"NCT04323436","phase":"PHASE2","title":"Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2020-08-19","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":31},{"nctId":"NCT03828747","phase":"PHASE2","title":"A Study of Semorinemab in Patients With Moderate Alzheimer's Disease","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2019-01-25","conditions":"Alzheimer's Disease","enrollment":272},{"nctId":"NCT02337283","phase":"PHASE1","title":"Safety, Tolerability, and Pharmacokinetics of Multiple Rising Doses of BI 425809 Tablets for 12 Days to Young and Elderly Healthy Male and Female Volunteers and Comparison of Pharmacokinetics of a Single Oral Dose of BI 425809 (Morning Versus Evening)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2015-01","conditions":"Healthy","enrollment":96},{"nctId":"NCT04913610","phase":"PHASE2","title":"Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-4083 Capsules When Given Alone or In Combination With Albendazole Capsules Moves in The Body of Adult Participants With Onchocerca Volvulus Infection","status":"TERMINATED","sponsor":"AbbVie","startDate":"2021-05-22","conditions":"Onchocerciasis","enrollment":153},{"nctId":"NCT04976855","phase":"PHASE1","title":"Study to Assess Repeated Doses of INDV-2000 in Healthy Volunteers and in Treatment Seeking Individuals With Opioid Use Disorder","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2022-08-17","conditions":"Healthy Volunteer, Opioid-use Disorder","enrollment":64},{"nctId":"NCT05202327","phase":"PHASE2","title":"PDC-1421 Treatment in Adult Patients With ADHD","status":"COMPLETED","sponsor":"BioLite, Inc.","startDate":"2022-04-07","conditions":"Attention-Deficit Hyperactivity Disorder (ADHD)","enrollment":70},{"nctId":"NCT05576623","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of AdCLD-CoV19-1 OMI as a Booster: A SARS-CoV-2 (COVID-19) Preventive Vaccine","status":"COMPLETED","sponsor":"Cellid Co., Ltd.","startDate":"2022-09-14","conditions":"COVID-19, Vaccines","enrollment":320},{"nctId":"NCT06501066","phase":"PHASE1, PHASE2","title":"Mesenchymal Stem Cells for Frailty Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Meribank Biotech Co., Ltd.","startDate":"2024-06-03","conditions":"Pathologic Processes","enrollment":66},{"nctId":"NCT04902885","phase":"PHASE3","title":"Phase 3 Study Evaluating Efficacy, Safety and Pharmacokinetics of Trilaciclib In Small Cell Lung Cancer Patients","status":"COMPLETED","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","startDate":"2021-05-25","conditions":"Extensive-stage Small-cell Lung Cancer","enrollment":95},{"nctId":"NCT06217146","phase":"NA","title":"A Medical Cannabis Oil for Treatment of Agitation and Disruptive Behaviors in Subjects With Dementia.","status":"TERMINATED","sponsor":"M. H MediCane Ltd.","startDate":"2022-10-12","conditions":"Agitation,Psychomotor, Disruptive Behavior, Dementia","enrollment":24},{"nctId":"NCT01208207","phase":"PHASE3","title":"A Two-Part 26-Week Study of Etoricoxib as Treatment for Ankylosing Spondylitis (AS) (MK-0663-108)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2010-09-27","conditions":"Spondylitis, Ankylosing","enrollment":1015},{"nctId":"NCT06372626","phase":"PHASE1, PHASE2","title":"Study of ZG005 in Combination With Etoposide and Cisplatin in Participants With Advanced Neuroendocrine Carcinoma.","status":"RECRUITING","sponsor":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","startDate":"2024-05-30","conditions":"Neuroendocrine Carcinoma","enrollment":93},{"nctId":"NCT02599714","phase":"PHASE1","title":"Study of AZD2014 and Palbociclib in Patients With Estrogen Receptor Positive (ER+) Metastatic Breast Cancer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-12-07","conditions":"Advanced and Metastatic Breast Cancer","enrollment":54},{"nctId":"NCT04413552","phase":"PHASE1","title":"INDV-2000 First in Human","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2020-07-06","conditions":"Opioid Dependence","enrollment":73},{"nctId":"NCT00636207","phase":"PHASE1","title":"A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Inhaled Montelukast (MK-0476) in Participants With Mild or Moderate Asthma (MK-0476-380 AM3)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-08","conditions":"Asthma","enrollment":46},{"nctId":"NCT02746796","phase":"PHASE2, PHASE3","title":"Study of ONO-4538 in Gastric Cancer","status":"COMPLETED","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2016-03","conditions":"Gastric Cancer","enrollment":680},{"nctId":"NCT06279286","phase":"PHASE1, PHASE2","title":"Phase Ⅰb/Ⅱ Study of HS-10506 in Chinese Participants With Insomnia Disorder","status":"UNKNOWN","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","startDate":"2024-05","conditions":"Insomnia Disorder","enrollment":312},{"nctId":"NCT03920540","phase":"PHASE3","title":"A Study of GC1111 in Hunter Syndrom Patients","status":"COMPLETED","sponsor":"Green Cross Corporation","startDate":"2017-03-09","conditions":"Hunter Syndrome","enrollment":32},{"nctId":"NCT04435392","phase":"PHASE1, PHASE2","title":"Jaktinib Hydrochloride Cream For Atopic Dermatitis","status":"COMPLETED","sponsor":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","startDate":"2020-10-14","conditions":"Atopic Dermatitis","enrollment":107}],"_emaApprovals":[],"_faersSignals":[],"crossReferences":{"chemblId":"CHEMBL20226"},"_approvalHistory":[],"publicationCount":259,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["iron sucrose injection - Venofer","regular dose of Daunorubicin (Arm I)","higher dose of Daunorubicin (ArmI)","Saline","Atacan Tab. 8 mg(or Atacan Tab. 16 mg), Norvasc Tab. 5 mg"],"phase":"marketed","status":"active","brandName":"Placebo Part II","genericName":"Placebo Part II","companyName":"Orion Corporation, Orion Pharma","companyId":"orion-corporation-orion-pharma","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T02:36:05.325211+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}